Loading…
← CockpitCompetitor Analysis › 002294.SZ Shenzhen Salubris Pharmaceuticals Co., Ltd. Class AOpen in the cockpit ↗

Shenzhen Salubris Pharmaceuticals Co., Ltd. Class A002294.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major

Shenzhen-based pharma company focused on cardiovascular and metabolic drugs, expanding into innovative biologics.

Momentum weak 32
Mkt cap
$4.31B
US dollars, full cap
Free float
40%
of shares outstanding
$/day
$54.6M
20-day average traded
Fwd P/E
35.4×
forward earnings
ROIC−WACC
+2.9 pp
WACC 5.0%
Hurdle
+3 pp
Req g minus delivered
Next earnings
132 days
30 Mar 2027
Close · CNYCN¥26.80
1D+0.5%
1W-11.0%
1M-14.9%
3M-25.1%
6M-24.0%
YTD-45.9%
1Y-53.4%
ATR %3.5%
52w lowhigh62.2% off high

What Shenzhen Salubris Pharmaceuticals does

Shenzhen-based pharma company focused on cardiovascular and metabolic drugs, expanding into innovative biologics.

Sells mainly cardiovascular prescription drugs to hospitals; its original mainstay, the anti-clot drug clopidogrel, lost ground when China's state volume-based purchasing rounds forced generic prices down. It has since leaned on newer heart-failure and blood-pressure drugs and is investing in biologic medicines still in development.

Products and services

  • Cardiovascular drugs
  • Metabolic disease drugs
  • Innovative biologics pipeline

Customers

  • Hospitals
  • Pharmacies/patients via prescriptions

Where it sits in the supply chain

  • Health Care
  • Pharmaceuticals
  • Cardiovascular/metabolic drugs +…

What could go right

  • Chronic-disease drug demand growth in China

What could go wrong

  • Centralized drug procurement (VBP) price cuts
  • Pipeline execution risk

Moat: narrow (brand, regulatory licence). Established cardiovascular drug franchise and regulatory approvals built over two decades.

Headquarters: Shenzhen, China · Employees: 4,087

Named competitors

Shenzhen Salubris Pharmaceuticals at a glance

Size Shenzhen Salubris Pharmaceuticals (002294.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $4.31B, the 558th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥26.80 on 18 Nov 2026.

Performance Over six months the shares fell 24.0%, against +10.4% for the median peer and -20.0% for the China market (cap-weighted) — 3rd lowest of 20 in its peer set.

Growth Revenue grew 14.2% over the last twelve months (peer median +3.0%); the operating margin is 11.3% (peer median 17.5%).

Valuation It trades at 35.4× forward earnings against a peer median of 25.2× (5th most expensive of 17).

Price implies For today's price to make sense, revenue must grow about 12% a year for seven years (Req g). Recent delivered growth is +10%, so the hurdle is +3 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 2.9 points above its cost of capital (5.0% WACC).

Next results Next results expected around 30 Mar 2027 (exchange calendar; dates can move).

Relative performance

8010012021 May 202621 Aug 202618 Nov 2026Peer median 111002294.SZ 77
Six months, rebased to 100: Shenzhen Salubris Pharmaceuticals against the median of its 20 peers (local-currency closes).

Shenzhen Salubris Pharmaceuticals financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥4.85BCN¥4.31BCN¥3.98BCN¥3.34BCN¥3.45B
Revenue growth—+8%+19%-3%—
Gross profitCN¥3.86BCN¥3.13BCN¥2.81BCN¥2.21BCN¥2.37B
EBITDAn/aCN¥1.07BCN¥1.08BCN¥927MCN¥922M
Net incomeCN¥715MCN¥652MCN¥602MCN¥580MCN¥637M
Free cash flowCN¥200MCN¥144MCN¥607MCN¥199MCN¥379M
Capital expenditureCN¥1.00BCN¥974MCN¥625MCN¥671MCN¥599M
Total debtCN¥966MCN¥711MCN¥134MCN¥63.5MCN¥614M

Quarterly statements and history in the cockpit →

Shenzhen Salubris Pharmaceuticals competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%-25%0%+25%-25%0%+25%CAMX600566AJANTPHARM6003324536000100IONSDFTX128940EMCUREGLAXOTVTXERAS688336600085ROVI002294.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Shenzhen Salubris Pharmaceuticals is the large dot.

Fundamentals: revenue growth against valuation

0%+100%+200%20×30×40×CAMX600566AJANTPHARM600332000100EMCUREGLAXOTVTX600079688336600085600329ROVI002294.SZRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Shenzhen Salubris Pharmaceuticals is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%+60%0%20%40%60%CAMX600566AJANTPHARM6003324536128940EMCURE301569GLAXOTVTX600079688336600329ROVI002294.SZGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Shenzhen Salubris Pharmaceuticals is the large dot.

Shenzhen Salubris Pharmaceuticals competitors and peer comparison

Head to head with its named competitors (002294.SZ vs 600276.SS vs 000513.SZ vs 1093.HK)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Shenzhen Salubris Pharmaceuticals 002294.SZ$4.31B-24%+14%11%35.4×12.4%
Jiangsu Hengrui Pharmaceuticals 600276.SS$45.7B-13%+6%27%33.4×13.4%
Livzon Pharmaceutical 000513.SZ$3.76B+4%-14%19%16.9×-9.6%
Cspc Pharma 1093.HK$12.0B+10%+25%28%9.1×-10.7%
Huadong Medicine 000963.SZ$6.69B-18%+2%9%12.5×-3.9%
Sbp 1177.HK$12.2B+5%+15%30%17.5×-5.7%

How Shenzhen Salubris Pharmaceuticals compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Shenzhen Salubris Pharmaceuticals against its 20 peers (data as of 18 Nov 2026)
Measure002294.SZPeer medianRank in peer set
1-month return-14.9%-1.3%5th lowest of 21
6-month return-24.0%+10.4%3rd lowest of 20
Distance from 52-week high-62.2%-25.9%2nd lowest of 21
Revenue growth (TTM)+14.2%+3.0%6th highest of 19
Operating margin11.3%17.5%6th lowest of 19
Forward P/E35.4×25.2×5th most expensive of 17
Growth the price implies (Req g, 7 yrs)12.4%3.2%7th most demanding of 17
Growth delivered (Del g)+9.7%+5.8%7th highest of 17
Hurdle (Req g minus delivered)+2.7 pp-5.0 pp6th most demanding of 17
ROIC minus cost of capital+2.9 pp+7.0 pp7th lowest of 19

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Shenzhen Salubris Pharmaceuticals 002294.SZChina$4.31B-24%+14%11%35.4×12.4%+9.7%
Camurus CAMX.STSweden$4.36B+36%+3%38%45.1×7.9%+46.5%
HUBEI JUMPCAN PHARMACEUTICAL 600566.SSChina$4.36B+12%-4%32%16.2×-9.9%+0.3%
Ajanta Pharma AJANTPHARM.NSIndia$4.38B+1%+25%25%31.7×23.8%+13.8%
Guangzhou Baiyunshan Pharmaceutical 600332.SSChina$4.45B-13%+1%3%12.9×-0.7%+4.7%
Santen Pharmaceutical 4536.TJapan$4.14B+10%+2%16%16.7×-5.0%+3.2%
Yuhan 000100.KSSouth Korea$4.11B-10%+8%6%40.4×n/an/a
Ionis Pharmaceuticals IONSUnited States$4.56B-64%-1%-59%n/an/an/a
Definium Therapeutics DFTXUnited States$3.99B+40%n/an/an/an/an/a
HanmiPharm 128940.KSSouth Korea$3.95B-2%+14%16%15.0×4.7%+7.5%
Emcure Pharmaceuticals EMCURE.NSIndia$4.74B+37%+21%16%33.6×15.9%+12.7%
Novast Laboratories 301569.SZChina$3.92Bn/a+3%27%n/a57.4%+3.1%
GlaxoSmithKline Pharmaceuticals GLAXO.NSIndia$4.79B+10%+12%33%37.3×26.4%+5.5%
Travere Therapeutics TVTXUnited States$4.82B+16%+49%-3%17.1×17.3%+19.9%
Erasca ERASUnited States$4.83B+24%n/an/an/an/an/a
Humanwell Healthcare (Group) 600079.SSChina$4.87B+11%+2%15%13.8×-8.8%+3.0%
Sunshine Guojian Pharmaceutical (Shanghai) 688336.SSChina$3.81B-38%+227%74%39.9×0.9%+45.1%
Beijing TongRenTang 600085.SSChina$4.91B-12%-17%8%28.7×1.7%+6.2%
Livzon Pharmaceutical 000513.SZChina$3.76B+4%-14%19%16.9×-9.6%+2.7%
Tianjin Pharmaceutical Da Ren Tang 600329.SSChina$3.75B-10%-13%20%28.5×16.2%-5.8%
Laboratorios Farmaceuticos Rovi ROVI.MCSpain$3.75B+12%+14%20%21.9×1.2%+12.1%

Questions

Who are Shenzhen Salubris Pharmaceuticals's main competitors?
Named competitors: Jiangsu Hengrui Pharmaceuticals (600276.SS), Livzon Pharmaceutical Group (000513.SZ), CSPC Pharmaceutical Group (1093.HK), Huadong Medicine (000963.SZ), Sino Biopharmaceutical (1177.HK). The cockpit's measured peer set (industry) also includes Camurus (CAMX.ST), HUBEI JUMPCAN PHARMACEUTICAL (600566.SS), Ajanta Pharma (AJANTPHARM.NS), Guangzhou Baiyunshan Pharmaceutical (600332.SS), Santen Pharmaceutical (4536.T), Yuhan (000100.KS).
Is Shenzhen Salubris Pharmaceuticals expensive compared with its peers?
On forward p/e it trades at 35.4× against a peer median of 25.2×, 5th most expensive of 17 in its peer set. For today's price to make sense, revenue must grow about 12% a year for seven years (Req g). Recent delivered growth is +10%, so the hurdle is +3 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Shenzhen Salubris Pharmaceuticals stock performed?
Over six months to 18 Nov 2026 the shares returned -24.0% against +10.4% for the median peer; over one year -53.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.